logo

For the Inventor, By the Inventor

Newark, DE, United States of America

John J Duncia

USPTO Granted Patents = 30

Average Co-Inventor Count = 2.8

ph-index = 17

Forward Citations = 791(Granted Patents)


Location History:

  • Newark, DE (US) (1989 - 1994)
  • Wilmington, DE (US) (1993 - 1997)

Company Filing History:

goldMedal25 out of 16,338 
 
E.i. Dupont De Nemours and Company
 patents
silverMedal5 out of 206 
 
The Dupont Merck Pharmaceutical Company
 patents

Years Active: 1989-1997

Loading Chart...
30 patents (USPTO):Explore Patents
1. 5698538 - Boronic acid and ester inhibitors of thrombin (1997-12-16),
2. 5563127 - Boronic acid and ester inhibitors of thrombin (1996-10-08),
3. 5545651 - Imidazole 5-position substituted angiotensin II antagonists (1996-08-13),
4. 5395844 - Imidazole 5-position substituted angiotensin II antagonists (1995-03-07),
5. 5376666 - Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl (1994-12-27),
6. 5354867 - Angiotensin II receptor blocking imidazoles (1994-10-11),
7. 5332820 - Dibenzobicyclo(2.2.2) octane angiotensin II antagonists (1994-07-26),
8. 5315013 - Substituted pyrazole angiotensin II antagonists (1994-05-24),
9. 5254546 - Fused aryl substituted imidazole angiotensin II receptor inhibitors (1993-10-19),
10. 5210079 - Treatment of chronic renal failure with imidazole angiotensin-II (1993-05-11),
11. 5189048 - Substituted 1,2,3 triazole angiotensin II antagonists (1993-02-23),
12. 5179113 - Treatment of central nervous disorders with imidazole compounds (1993-01-12),
13. 5173494 - Specific inhibition of angiotensin-II binding to angiotensin-II receptor (1992-12-22),
14. 5155126 - Treatment of central nervous system disorders with pyrazole, pyrrole and (1992-10-13),
15. 5155118 - Method and composition for preventing NSAID-induced renal failure (1992-10-13),

Title: John J Duncia: Innovator in Thrombin Inhibitors

Introduction: John J Duncia, based in Newark, DE, is a prolific inventor with an impressive portfolio of 30 patents. His work primarily focuses on the development of novel compounds that have significant implications in the field of biochemistry and pharmaceuticals.

Latest Patents: Among his latest contributions to science, Duncia has introduced groundbreaking patents such as "Boronic Acid and Ester Inhibitors of Thrombin." These compounds include novel boronic acid and ester, as well as carboxyl-modified amino acid compounds that serve as inhibitors of trypsin-like enzymes. This innovative work underscores his commitment to advancing therapeutic solutions.

Career Highlights: Duncia has had a distinguished career with roles at notable companies, including E.I. DuPont de Nemours and Company and The DuPont Merck Pharmaceutical Company. His contributions in these organizations have been pivotal in driving forward important research and development initiatives.

Collaborations: Throughout his career, Duncia has collaborated with prominent figures in the industry, including David J. Carini and Pancras C. Wong. Their collective expertise has enriched the research environment and fostered innovative ideas that have led to impactful patents.

Conclusion: John J Duncia's contributions to the field of thrombin inhibitors not only highlight his skills as an inventor but also emphasize the importance of collaboration and innovation in scientific research. With a robust patent portfolio and a dedication to advancing healthcare solutions, Duncia's work continues to make a significant impact.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…